

Freedom of Information Act 2000 – Request Reference FoI/23/606
New Biologic and Targeted Medications

Q1. How many patients were treated in October 2023 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo): 1
- Baricitinib (Olumiant): 2
- Dupilumab (Dupixent): 44
- Omalizumab (Xolair): 5
- Tralokinumab (Adtralza): 1
- Upadacitinib (Rinvoq): 4

Q2. How many patients were treated in October 2023 (or latest available month) by the Respiratory Medicine department with the following drugs:

- Benralizumab (Fasenra): 25
- Dupilumab (Dupixent): 27
- Mepolizumab (Nucala): 15
- Omalizumab (Xolair): 7
- Reslizumab (Cinqaero): 0
- Tezepelumab (Tezspire): 21